journal article·2025-04-02

A Nanoradiosensitizer Potentiates Tumor Radiotherapy through JFK Inhibition and Hypoxia Alleviation

Jianze Wang, Qianrui Guo, Lin He, Rui Song, Jinhong Du, Haoyi Zhou, Yameng Hao, Xiujie Yang, Feng Wang, Kui Li, Mo Li, Zhi Yang, Luyang Sun, Zhaofei Liu

Nano Letters· Volume 25· Issue 13
Publisher page

Abstract

Radiotherapy (RT) is a primary treatment for breast cancer, but its effectiveness is often compromised by hypoxia and intrinsic resistance mechanisms. The F-box protein JFK is overexpressed in breast cancer and is associated with reduced radiosensitivity, but specific JFK inhibitors are currently unavailable. Herein, we developed spherical nanoparticles (SNP-JC) designed to co-deliver small interfering RNA targeting JFK and catalase to the tumor, aiming to silence JFK and alleviate hypoxia to overcome RT resistance. Positron emission tomography imaging demonstrated that SNP-JC efficiently accumulated in the tumors. SNP-JC significantly increased DNA damage in tumor cells after RT and promoted the immunogenic cell death. The combination of SNP-JC and RT activated CD8 + T cells and elicited a robust antitumor immunity, resulting in suppressed primary tumor growth and reduced lung metastasis. Our findings demonstrate that a nanoplatform capable of simultaneously silencing JFK and mitigating hypoxia can enhance tumor radiosensitivity, improve antitumor efficacy, and prevent metastasis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · MicroRNA in disease regulation · Hydrogen's biological and therapeutic effects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, and Department of Nuclear Medicine, Peking University Cancer Hospital and Institute

Institute of Medical Technology

Peking University Health Science Center

Department of Biochemistry, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration)

Peking University Cancer Hospital and Institute

State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology

Peking University Third Hospital

State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Nuclear Medicine

Funding

Peking University · National Key Research and Development Program of China · Natural Science Foundation of Beijing Municipality · National Natural Science Foundation of China

References (44)

Show source-provided references
1. 10.1016/j.cell.2023.01.04010.1016/j.cell.2023.01.040 ↗
2. 10.3322/caac.2170810.3322/caac.21708 ↗
3. 10.1038/s41571-023-00782-x10.1038/s41571-023-00782-x ↗
4. 10.1038/s41568-020-0246-110.1038/s41568-020-0246-1 ↗
5. 10.1021/acsnano.3c1022510.1021/acsnano.3c10225 ↗
6. 10.1038/nrc395810.1038/nrc3958 ↗
7. 10.1186/s12943-023-01839-210.1186/s12943-023-01839-2 ↗
8. 10.1038/s41392-020-0150-x10.1038/s41392-020-0150-x ↗
9. 10.1016/j.radonc.2023.10973810.1016/j.radonc.2023.109738 ↗
10. 10.1158/1078-0432.CCR-12-085810.1158/1078-0432.CCR-12-0858 ↗
11. 10.1016/j.semcancer.2023.11.00610.1016/j.semcancer.2023.11.006 ↗
12. 10.1038/ncomms1230810.1038/ncomms12308 ↗
13. 10.1016/j.semcancer.2023.11.00810.1016/j.semcancer.2023.11.008 ↗
14. 10.1038/s41467-023-41782-w10.1038/s41467-023-41782-w ↗
15. 10.1021/acsnano.1c0003310.1021/acsnano.1c00033 ↗
16. 10.1002/adma.20180222810.1002/adma.201802228 ↗
17. 10.1016/j.biomaterials.2017.05.02510.1016/j.biomaterials.2017.05.025 ↗
18. 10.1172/JCI13609810.1172/JCI136098 ↗
19. 10.1038/s41392-021-00735-910.1038/s41392-021-00735-9 ↗
20. 10.1016/j.canlet.2023.21607810.1016/j.canlet.2023.216078 ↗
21. 10.1073/pnas.090186410610.1073/pnas.0901864106 ↗
22. 10.1101/gad.254292.11410.1101/gad.254292.114 ↗
23. 10.3389/fcell.2021.68673710.3389/fcell.2021.686737 ↗
24. 10.1021/jacs.8b0937410.1021/jacs.8b09374 ↗
25. 10.1002/anie.20191061510.1002/anie.201910615 ↗
26. 10.1007/s00259-022-05711-110.1007/s00259-022-05711-1 ↗
27. 10.1038/nri91110.1038/nri911 ↗
28. 10.1172/JCI16106510.1172/JCI161065 ↗
29. 10.1016/j.biomaterials.2016.01.02710.1016/j.biomaterials.2016.01.027 ↗
30. 10.1038/s41576-021-00439-410.1038/s41576-021-00439-4 ↗
31. 10.1038/s41392-022-01298-z10.1038/s41392-022-01298-z ↗
32. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
33. 10.1038/nbt.261210.1038/nbt.2612 ↗
34. 10.1038/s41565-021-00898-010.1038/s41565-021-00898-0 ↗
35. 10.1038/s41571-023-00811-910.1038/s41571-023-00811-9 ↗
36. 10.1186/s12943-023-01797-910.1186/s12943-023-01797-9 ↗
37. 10.1002/adma.20230624610.1002/adma.202306246 ↗
38. 10.1016/j.addr.2022.11441710.1016/j.addr.2022.114417 ↗
39. 10.1016/j.apsb.2022.03.01710.1016/j.apsb.2022.03.017 ↗
40. 10.1038/s41575-019-0247-210.1038/s41575-019-0247-2 ↗
41. 10.1002/advs.20230890510.1002/advs.202308905 ↗
42. 10.1016/j.jconrel.2023.03.00210.1016/j.jconrel.2023.03.002 ↗
43. 10.1038/s41467-023-37656-w10.1038/s41467-023-37656-w ↗
44. 10.1016/j.addr.2017.12.01510.1016/j.addr.2017.12.015 ↗